Jefferies Financial Group Inc. Invests $1.52 Million in Omnicell, Inc. $OMCL

Jefferies Financial Group Inc. acquired a new position in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 36,712 shares of the company’s stock, valued at approximately $1,524,000.

Other hedge funds have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio acquired a new position in Omnicell during the 2nd quarter valued at about $2,253,000. Corient Private Wealth LP acquired a new stake in shares of Omnicell in the second quarter valued at approximately $2,608,000. Odyssean LLC bought a new stake in shares of Omnicell during the second quarter valued at approximately $2,235,000. Man Group plc acquired a new position in shares of Omnicell during the second quarter worth approximately $3,170,000. Finally, Jupiter Topco LLC bought a new position in Omnicell in the 2nd quarter worth approximately $883,000. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

OMCL has been the topic of several analyst reports. Piper Sandler restated an “overweight” rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Finally, Wells Fargo & Company reduced their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Stock Down 1.0%

Shares of OMCL stock opened at $33.08 on Friday. Omnicell, Inc. has a 1 year low of $29.06 and a 1 year high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The business’s fifty day moving average is $39.80 and its 200-day moving average is $39.33. The stock has a market cap of $1.50 billion, a PE ratio of 39.38, a price-to-earnings-growth ratio of 0.83 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities analysts expect that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.